{Reference Type}: Journal Article
{Title}: S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
{Author}: Deckers EA;Wevers KP;Muller Kobold AC;Damude S;Vrielink OM;van Ginkel RJ;Been LB;van Leeuwen BL;Hoekstra HJ;Kruijff S;
{Journal}: J Surg Oncol
{Volume}: 120
{Issue}: 6
{Year}: Nov 2019
{Factor}: 2.885
{DOI}: 10.1002/jso.25682
{Abstract}: <B>OBJECTIVE: </B>This current study assessed the value of S-100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients.<BR><B>METHODS: </B>This study included 100 stage III melanoma patients in follow-up after curative lymph node dissection. Follow-up visits included physical examination and S-100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S-100B.<BR><B>RESULTS: </B>Of 100 patients, 13 (13%) had elevated S-100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty-six patients (26%) had clinical symptoms with normal S-100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S-100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S-100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow-up, 23% of all patients with recurrent disease.<BR><B>CONCLUSIONS: </B>S-100B cannot exclude recurrent disease during follow-up of stage III melanoma. However, adding S-100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.